Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

Rivera, Fernando; Izquierdo-Manuel, Marta; García‐Alfonso, Pilar; Castro, Eva Martínez de; Gállego, Javier; Limón, María Luisa; Alsina, María; López, L.; Galán, Maica; Falcó, Esther; Manzano, José Luís; González, Elena Navarro; López, Carlos; Aranda, Enrique; Fernández, Eva; Jorge, Mónica; Jiménez‐Fonseca, Paula

doi:10.1016/j.ejca.2020.12.005

Cited by 38 publications

(28 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The included studies demonstrated feasibility of the addition of trastuzumab to conventional cytotoxic therapy. [16][17][18]23,25] No increase in treatment-related toxicities, as well as no unexpected safety findings were observed by adding trastuzumab to the treatment regimens. [16][17][18]25] Two studies reported relatively high incidences of grade ≥3 diarrhea (33%) and neutropenia (28%), although toxicities were manageable.…”

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 96%

“…[16][17][18]23,25] No increase in treatment-related toxicities, as well as no unexpected safety findings were observed by adding trastuzumab to the treatment regimens. [16][17][18]25] Two studies reported relatively high incidences of grade ≥3 diarrhea (33%) and neutropenia (28%), although toxicities were manageable. [17,18] Furthermore, trastuzumab did not result in an increase of cardiac toxicity, with a mean left ventricular ejection fraction of 57% pre-treatment compared to 56% posttreatment in a phase I/II trial [15], as well as no reported cardiotoxicity in a large randomized study with 203 patients.…”

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 96%

“…Several studies investigated the tolerability and efficacy of the addition of trastuzumab to chemo(radio)therapy for the curative treatment of patients with HER2 positive GEA. [15][16][17][18]23] The majority of studies were small nonrandomized phase I/II studies (n=36, range 19-203), reporting on the safety and efficacy of the addition of trastuzumab to neoadjuvant, perioperative, or adjuvant chemo(radio)therapy. The included studies demonstrated feasibility of the addition of trastuzumab to conventional cytotoxic therapy.…”

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

“…[16][17][18]25] Two studies reported relatively high incidences of grade ≥3 diarrhea (33%) and neutropenia (28%), although toxicities were manageable. [17,18] Furthermore, trastuzumab did not result in an increase of cardiac toxicity, with a mean left ventricular ejection fraction of 57% pre-treatment compared to 56% posttreatment in a phase I/II trial [15], as well as no reported cardiotoxicity in a large randomized study with 203 patients. [25] However, a phase II study observed one severe cardiac disorder, potentially attributable to the addition of trastuzumab to FLOT.…”

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

“…[17] The pathological complete response (pCR) rate was 16% (range 9.6-22.2%) in three studies. [16][17][18] On the other hand, no survival benefit was demonstrated with the addition of trastuzumab to six weeks of chemoradiotherapy in preliminary results of a large randomized study (n=203). [25] The median Three ongoing studies currently assessing the addition of trastuzumab to chemo(radio)therapy are listed in Table 2.…”

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

See 4 more Smart Citations

A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead

Stroes

Ende

Derks

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 96%

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 96%

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

Section: Single Her2 Targeting With Trastuzumabmentioning

confidence: 99%

See 3 more Smart Citations

A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead

Stroes

Ende

Derks

et al. 2021

Cancer Treatment Reviews

View full text Add to dashboard Cite

show abstract

Surgical Management of Gastric Cancer

2022

View full text Add to dashboard Cite

he incidence of gastric cancer has decreased worldwide since the 1970s owing to factors such as improved refrigeration 1 and effective therapy against Helicobacter pylori. 2 However, prognosis for patients with gastric cancer has only modestly improved during this time, probably because patients often present with advanced disease. In the US, up to 65% of patients present with stage III or IV disease, and even in countries like Japan with robust screening programs, half of patients still present with advanced disease. 3 As a result, gastric cancer remains the third most common cause of cancer mortality worldwide, 4 and in the US, there are still 27 000 new cases and 11 000 deaths each year. 5 Treatment of gastric cancer requires a multidisciplinary approach and continues to evolve. Here, we review the contemporary surgical management of all stages of gastric cancer. Early Gastric CancerEarly gastric cancer (EGC) is defined as a tumor limited to the mucosa or submucosa (clinical T1) regardless of lymph node status. 6 The risk of lymph node involvement dictates the subsequent management of EGCs. Endoscopic TherapyGastric cT1a tumors that are less than 2 cm in diameter, lack ulceration with differentiated histology, have no lymphovascular inva-sion, and lack clinical evidence of locoregional lymph node involvement have a low 1% to 5% risk of lymph node metastasis. 7,8 Patients with these tumors are thus candidates for curative-intent endoscopic therapy with either endoscopic mucosal resection or endoscopic submucosal dissection. 9,10 Although a propensity scorematched analysis of data from the National Cancer Database found that gastrectomy was associated with superior survival compared with endoscopic resection for cT1a tumors, it is unclear what proportion of these tumors met the other criteria for endoscopic resection. 8 Furthermore, other Eastern and Western series have reported excellent long-term outcomes after endoscopic resection in appropriately selected patients, 9,10 and currently the Japanese Gastric Cancer Association, 11 European Society of Medical Oncology, 12 and National Comprehensive Cancer Network (NCCN) 13 all recommend endoscopic therapy as initial therapy for EGC meeting the previously mentioned criteria. All patients with gastric cancer should undergo H pylori testing and eradication therapy if test results are positive, but this is especially important for patients with EGC who are undergoing endoscopic resection, as H pylori eradication decreases the risk of developing metachronous gastric cancers. 14 In contrast, gastric cT1b tumors have nodal metastasis rates of 18% to 32%, 8,15 and a radical gastrectomy (ie, one that includes a formal lymphadenectomy) should be considered for patients with these tumors. Patients who undergo noncurative endoscopic resection, ie, those with positive margins, lymphovascular invasion, or poorly differentiated histology on final pathology, also have a 14% IMPORTANCE Surgery plays a critical role in the management of all stages of gastric cancer.OBSERVATIONS Fo...

show abstract

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Wang,

Ye,

et al. 2024

MedComm

View full text Add to dashboard Cite

Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its highest incidence and mortality rates reported in China. The complex molecular mechanisms underlying EC, coupled with the differential incidence of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) across various regions, highlight the necessity for in‐depth research targeting molecular pathogenesis and innovative treatment strategies. Despite recent progress in targeted therapy and immunotherapy, challenges such as drug resistance and the lack of effective biomarkers for patient selection persist, impeding the optimization of therapeutic outcomes. Our review delves into the molecular pathology of EC, emphasizing genetic and epigenetic alterations, aberrant signaling pathways, tumor microenvironment factors, and the mechanisms of metastasis and immune evasion. We further scrutinize the current landscape of targeted therapies, including the roles of EGFR, HER2, and VEGFR, alongside the transformative impact of ICIs. The discussion extends to evaluating combination therapies, spotlighting the synergy between targeted and immune‐mediated treatments, and introduces the burgeoning domain of antibody–drug conjugates, bispecific antibodies, and multitarget‐directed ligands. This review lies in its holistic synthesis of EC's molecular underpinnings and therapeutic interventions, fused with an outlook on future directions including overcoming resistance mechanisms, biomarker discovery, and the potential of novel drug formulations.

show abstract

Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial

Cited by 38 publications

References 30 publications

A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead

A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead

Surgical Management of Gastric Cancer

Targeting esophageal carcinoma: molecular mechanisms and clinical studies

Contact Info

Product

Resources

About